




# PHARMACEUTICAL 2021

Cartesian Therapeutics Inc.  
Rank 320 of 402





RealRate

# PHARMACEUTICAL 2021

## Cartesian Therapeutics Inc. Rank 320 of 402



The relative strengths and weaknesses of Cartesian Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cartesian Therapeutics Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 20% points. The greatest weakness of Cartesian Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 31% points.

The company's Economic Capital Ratio, given in the ranking table, is -57%, being 105% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	151,343
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	81,547
Liabilities, Non-Current	48,393
Other Assets	12,697
Other Compr. Net Income	-40
Other Expenses	11,999
Other Liabilities	53,501
Other Net Income	-56
Other Revenues	16,597
Property and Equipment	1,395
Research and Development	54,505
Selling, General and Administrative Expense	18,913

Output Variable	Value in 1000 USD
Assets	165,435
Liabilities	183,441
Expenses	85,417
Revenues	16,597
Stockholders Equity	-18,006
Net Income	-68,876
Comprehensive Net Income	-68,896
Economic Capital Ratio	-57%